Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004403|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : March 25, 2015
OBJECTIVES: I. Determine the effect of antiparasitic treatment with albendazole on the severity and duration of epilepsy due to neurocysticercosis.
II. Determine the effect of a short course of albendazole on Taenia solium cysts present in the brain.
III. Determine the natural regression of cerebral T. solium cysts in patients given placebo and their response to treatment at the end of the study.
|Condition or disease||Intervention/treatment|
|Epilepsy Cysticercosis||Drug: albendazole Drug: dexamethasone Drug: phenytoin|
PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are randomized to receive either albendazole and dexamethasone or placebo.
Patients receive phenytoin daily starting on day 1 and continuing until seizure free for 1 year. Albendazole and dexamethasone or placebo only is administered orally once daily on days 5-15.
Patients are asked to maintain a diary. Patients are followed on day 15 and 30, then every 3 months for 3 years.
Completion date provided represents the completion date of the grant per OOPD records
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Study Start Date :||May 2000|
|Estimated Study Completion Date :||March 2002|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004403
|Study Chair:||Robert H. Gilman||Johns Hopkins University|